RNAi Therapy Gets Breakthrough Status for Primary Hyperoxaluria Type 1

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to DCR-PHXC (Dicerna Pharmaceuticals) for the treatment of patients with primary hyperoxaluria type 1 (caused by a mutation in the AGXT gene).

DCR-PHXC is a ribonucleic acid interference (RNAi) investigational treatment that works by inhibiting the lactate dehydrogenase A enzyme (LDHA) in the liver to reduce excess production of oxalate. The Breakthrough Therapy designation is supported by data from the PHYOX1 phase 1 trial which was recently presented at the Oxalosis and Hyperoxaluria Foundations’s International Workshop.

Results demonstrated significant post-dose reductions in 24 hour urinary oxalate levels in adults and adolescent patients with primary hyperoxaluria type 1 and type 2 (caused by a mutation in the GRHPR gene); additionally, urinary oxalate levels in a majority of patients were normalized or near-normal after a single dose of DCR-PHXC. Regarding safety, DCR-PHXC was generally well-tolerated.

“By granting Breakthrough Therapy designation, the FDA recognizes both the urgent need to develop a therapy for primary hyperoxaluria type 1 and the encouraging preliminary data from the PHYOX1 clinical trial of DCR-PHXC in these patients,” said Ralf Rosskamp, MD, Dicerna’s chief medical officer. “We look forward to continuing our dialogue with the FDA as we advance DCR-PHXC as quickly as possible as a potential therapeutic option for all persons living with primary hyperoxaluria.”

Related ArticlesARO-AAT Receives Fast Track Status for Treatment of Rare Genetic Liver DiseaseRNAi Therapeutic Gets Orphan Drug Status for Familial Chylomicronemia SyndromeNovel Treatment for Common Urea Cycle Disorder Gains Orphan Drug Status

The Company is currently enrolling patients in the PHYOX2 phase 2 trial and will continue discussions with the FDA to investigate end points for future DCR-PHXC studies in patients with primary hyperoxaluria type 2 and 3 (caused by a mutation in the HOGA1 gene).

For more information visit dicerna.com.

The post RNAi Therapy Gets Breakthrough Status for Primary Hyperoxaluria Type 1 appeared first on MPR.